Sudemycin K

• Description:

  Sudemycin K is a selective splicing inhibitor targeting SF3B1. Sudemycin K blocks U2 snRNP recognition of branch point sequences in pre-mRNA, inducing tumor-specific splicing deregulation and apoptosis. Sudemycin K is promising for research of SF3B1-mutated malignancies such as chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS) [1].

• UNSPSC:

  12352005

• Target:

  SF3B1

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Smiles:

  C[C@H](NC(C(C)C)=O)/C=C\C(NC1CCC(C/C=C(C)/C=C/[C@@H](OC(C)(C)C2)C[C@@]32CO3)CC1)=O

• Molecular Formula:

  C29H46N2O4

• Molecular Weight:

  486.69

• References & Citations:

  [1]Makowski K, et al. Sudemycin K: A Synthetic Antitumor Splicing Inhibitor Variant with Improved Activity and Versatile Chemistry. ACS Chem Biol. 2017 Jan 20;12 (1) :163-173.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2071636-70-7]